Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1641-1660 of 2,251 trials

Melanoma, Breast Cancer, and Head & Neck Cancer: Contrast-Enhanced Ultrasound Study

We are exploring whether contrast-enhanced ultrasound can better locate sentinel nodes during surgery compared to the current standard method. This study aims to improve detection and potentially predict if the nodes are cancerous.

Breast CancerMelanomaHead and Neck Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncologyOtolaryngology

Acute Myeloid Leukemia: Venetoclax and Azacitidine Study

We are comparing a new treatment combination with standard chemotherapy for patients with newly diagnosed acute myeloid leukemia and NPM1 mutations. The goal is to see if this new approach is more effective and easier to tolerate.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Grass Allergy: Vitamin D Enhanced Immunotherapy

We are studying whether combining intralymphatic immunotherapy with vitamin D helps improve allergy symptoms in people with moderate to severe grass allergies during pollen season.

Allergic Rhinitis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesAllergology

Multiple Myeloma: HDP-101 Treatment Study

We are testing a new treatment called HDP-101 for patients with relapsed or refractory multiple myeloma. The study aims to find a safe dose and evaluate how well it works.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Multiple Myeloma: New CAR-T Cell Therapy Study

We are testing a new CAR-T cell therapy for adults with relapsed or refractory multiple myeloma who have been treated with lenalidomide. The goal is to see if it works better than standard treatments currently available.

Relapsed/Refractory Multiple Myeloma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Congenital Hyperinsulinism: HM15136 Treatment Study

We are evaluating a new treatment for children with congenital hyperinsulinism to see if it is safe and helps reduce low blood sugar events. This study includes children aged 2 years and older.

Congenital Hyperinsulinism≤3 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyPediatrics

Epithelioid Malignant Pleural Mesothelioma: Atezolizumab and WT1/DC Vaccine

We are studying the safety and effectiveness of adding a new treatment to standard chemotherapy for patients with epithelioid malignant pleural mesothelioma. This trial aims to see if the combination improves treatment outcomes.

Malignant Pleural Mesothelioma6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Ovarian Cancer: Pembrolizumab with Chemotherapy

We are studying a new treatment combining pembrolizumab with chemotherapy for patients with small cell ovarian carcinoma. The goal is to see how well this combination works and to evaluate its safety.

Ovarian Small Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Oral Arsenic for Low-Risk Myelodysplastic Syndromes

We are studying whether oral arsenic can help patients with low-risk myelodysplastic syndromes who haven't responded to other treatments. The trial aims to assess its safety and effectiveness over 12 weeks.

Low-Risk Myelodysplastic Syndromes>2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Rhizarthrosis: Autologous Stromal Vascular Fraction Injection

We are studying the safety and effects of an injection using your own stem cells for treating rhizarthrosis. This trial will help us understand its impact on pain and joint function over several months.

Rhizarthrosis (Thumb Arthritis)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOrthopedics and TraumatologyRheumatology

CAR-T Cell Therapy: Understanding Extracellular Vesicles

We are studying how extracellular vesicles change before and after CAR-T cell treatment in patients, especially those experiencing neurotoxicity. This research may help improve patient care and treatment outcomes.

CAR T-cell Therapy>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesHematologyInfectious DiseasesOncology

Multiple Myeloma and Knee Surgery: Apixaban Study

We are comparing how the blood thinner Apixaban works in patients with newly diagnosed multiple myeloma and those undergoing knee replacement surgery. This study aims to understand its effects on blood clotting and how it behaves in the body.

Thromboembolism Prophylaxis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyHematologyOncology

Rectal Cancer: NanoEcho Imaging Study

We are exploring a new imaging method for examining rectal lymph nodes in healthy volunteers and rectal cancer patients. The goal is to assess safety and improve detection of lymph node involvement.

Rectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Schizophrenia: Biomarkers for Clozapine Response

We are investigating whether specific biomarkers can help predict how well individuals with schizophrenia respond to clozapine. This research may lead to more tailored treatments for those who need them.

Schizophrenia≤3 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNeurologyPsychiatry

Pancreatic Cancer: GEMBRAX and FOLFIRINOX Treatment Study

We are exploring a new treatment sequence for patients with locally advanced pancreatic cancer to see if it improves outcomes and tolerability. This study will help us understand its effects on survival and quality of life.

Non-resectable Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Breast Cancer: Trastuzumab-Deruxtecan Treatment Study

We are investigating if switching to a new drug can help patients with HR+ HER2 low metastatic breast cancer who are not responding well to standard therapy. This study aims to find out if this change improves survival and response rates.

Metastatic Breast CancerEfficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyOncology

Lower Risk MDS: Luspatercept and EPO Combination Study

We are studying a new treatment combining luspatercept with EPO for patients with lower risk MDS who haven't responded to previous therapies. The goal is to see if this combination helps improve blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Inflammatory Bowel Disease: Risankizumab-800CW Imaging Study

We are investigating the safety and effectiveness of a new imaging agent for patients with Inflammatory Bowel Disease. This study aims to improve how we visualize drug targeting and inflammation in the intestines.

Inflammatory Bowel Disease (IBD)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyInfectious Diseases

Heart Procedure: Single vs. Dual Antiplatelet Therapy

We are comparing a single medication to a combination of two medications for patients after a heart procedure. The goal is to see if the single medication is just as safe and effective while reducing bleeding risks.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Pneumococcal Vaccine Response in Patients Without a Spleen

We are studying how the timing of pneumococcal vaccination affects immune response in patients who have had their spleen removed. This research may help improve vaccination strategies for asplenic individuals.

Asplenia>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementAllergologyHematologyInfectious Diseases